This site is for US Healthcare Professionals only.

  • Approximately 22% of patients with diabetes have NASH5
  • Significant liver fibrosis has been observed in approximately 13% of patients with T2DM, and cirrhosis was found in 6% of these patients6
    In this study, the prevalence of steatosis, advanced fibrosis, and cirrhosis were evaluated in 133 adults >55 years of age using the NAFLD fibrosis score (NFS) and magnetic resonance imaging (MRI)6
  • Other metabolic disorders with an emerging association with NAFLD may include metabolic syndrome, dyslipidemia, polycystic ovarian syndrome, growth hormone deficiency, hypothyroidism, and hypogonadism7
The prevalence of NASH is known to fluctuate across various demographic factors5
  • Risk of NASH increases with age8
  • Men are more susceptible to NAFLD3 and NASH5 than women5
  • Consider screening patients with known risk factors3,6,9
    Being obese
    Type 2 diabetes diagnosis
NEXT: NASH Treatment Goals
BACK: NASH Overview

  1. Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L; American Association for the Study of Liver Diseases; United States Food and Drug Administration. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology. 2015;61(4):1392-1405.
  2. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142(7):1592-1609.
  3. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357.
  4. Younossi ZM, Stepanova M, Hallaji S, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore). 2012;91(6):319-327.
  5. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140(1):124-131.
  6. Arab JP, Barrera F, Gallego C, et al. High prevalence of undiagnosed liver cirrhosis and advanced fibrosis in type 2 diabetic patients. Ann Hepatol. 2016;15(5):721-728.
  7. Do A, Lim JK. Epidemiology of nonalcoholic fatty liver disease: a primer. Clin Liver Dis. 2016;7:106-108.
  8. Wong RJ, Liu B, Bhuket T. Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 National Health and Nutrition Examination Survey. Aliment Pharmacol Ther. 2017;46(10):974-980.
  9. Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clin Med (Lond). 2018;18(3):245-250.
  10. Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol. 2014;5(3):211-218.
  11. Schiff ER. Fibroscan (transient elastography) for the measurement of liver fibrosis. Adv Hepatol. 2012;8(9):605-607.
  12. Ofosu A, Ramai D, Reddy M. Non-alcoholic fatty liver disease: controlling an emerging epidemic, challenges, and future directions. Ann Gastroenterol. 2018;31(3):288-295.